SEC Form 4 · accession 0001209191-18-002240
AKCEA THERAPEUTICS, INC. · AKCA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paula Soteropoulos
Officer — President & CEO · Director
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 7:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001662524
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $17.38 | Jan 2, 2018 | A | 275,000 | A | — | Jan 1, 2028 | Common Stock | 275,000 | 275,000 | D |
Explanation of responses
- F1The shares vest as follows: 1/4th of the shares vest one year after January 2, 2018; 1/48th of the shares vest monthly thereafter over the next three years.